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Introduction
The management of acute coronary syndromes (ACS) is a true suc-
cess story. Indeed, in 1955 when the then President of the United
States Dwight D. Eisenhower had an infarction, the President’s per-
sonal physician, Dr Howard Snyder, interpreted his symptoms as a
gastrointestinal illness.1 It took 10 h to transfer him to a local hospital
where an electrocardiograph had to be brought in from another hos-
pital—a situation that today would be malpractice.2 The electrocar-
diogram (ECG) showed an anterolateral acute myocardial infarction
(AMI) with ST-segment elevation myocardial infarction or a STEMI as
we would call it today based on the recent definition of myocardial in-
farction (MI).3 Based on the Fourth Universal Definition of Myocardial
Infarction Eisenhower experienced a clear cut Type 1 infarction
(Table 1). Today, we distinguish not only five types of infarction, but
also myocardial injury, defined by an elevated cardiac troponin (cTn)
value, which is also associated with an adverse prognosis. To differen-
tiate myocardial injury from MI, criteria in addition to abnormal bio-
markers are required such as ECG changes and evidence of ischaemia.
In the 1950s not many diagnostic tools nor even any effective treat-
ment was available.4 Not only was an ECG not commonly available,
cardiac enzymes were still to be introduced and unavailable at that
time. The management of AMI was mainly ‘tender loving care’, i.e.
nitroglycerine and morphine for pain relief. Defibrillation had still to
be introduced by Paul M. Zoll a year later.5 Aspirin (ASA) was labelled
as remedy for fever and pain and considered contraindicated for heart
patients6 until Sir John Vane discovered that it inhibits platelet aggrega-
tion,7 Betablockers had still to be developed by Sir James Black, Nobel
Prize Laureate in 1988.8 Finally, Akiro Endo’s seminal discovery of sta-
tins only occurred in the 1970s9 and shown to reduce mortality as
late as 1992.10 Lastly, it took another couple years until inhibitors of
the P2Y12 receptor became common practice.
11,12 The most import-
ant step, proved to be rapid and effective reperfusion and revasculari-
zation. Although streptokinase and later tissue plasminogen activators
were somewhat successful, it required a bold colleague such as
Andreas R. Gru¨ntzig to develop percutaneous coronary intervention
(PCI).13,14 Later, stents (and especially drug eluting stents) improved
the results of primary percutaneous coronary angioplasty and made it
the first line therapy in patients with ACS.15,16 As a result of all these
impressive developments, mortality of AMI declined stepwise, but
eventually dramatically over the past decade17 (Figure 1). Again this
year further steps have been taken to improve the management of
patients with ACS as outlined in this review.
The studies included in this review deal initially with pathophysio-
logic mechanisms, early diagnosis, risk stratification, and outcomes in
specific subpopulations, the mid portion reports new data on
pharmacotherapy while the last part provides latest data on interven-
tional treatment of ACS.
Mechanisms
Alterations of innate and adaptive
immunity
In patients with ACS, the higher activity of effector T-cells suggests
that mechanisms involving adaptive immunity dysregulation might
play a role in coronary instability. The shedding of the functional
CD31 domain 1–5 leads to uncontrolled lymphocyte activation.
Flego et al.18 found that enhanced MMP-9 release plays a key role in
determining the cleavage and shedding of the functional CD31 do-
main 1–5 in CD4þ T-cells of ACS patients. They propose the follow-
ing sequence of events in ACS and systemic evidence of
inflammation: MMP-9, released by innate immunity cells and by T-
cells, causes the cleavage of CD31 domain 1–5; the increased expres-
sion of MMP-9 might affect TCR-dependent T-cell activation and in-
duce T-cell hyper-reactivity, through the alteration of cellular
pathways linked to CD31 cleavage. They also propose that molecules
such as MMP-9 and CD31, could represent desirable molecular tar-
gets for specific anti-inflammatory treatments and might be used as
clinical biomarkers of prognosis in patients with ACS.
* Corresponding author. Tel: þ39063051166, Fax: þ39063055535, e-mail: filippo.crea@unicatt.it
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
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Plaque erosion on the rise
At least one-third of ACS are caused by plaque erosion and with its
recognition the prevalence is probably increasing.19 Dai et al. assessed
the culprit plaque in 822 patients present STEMI by optical coherence
tomography (OCT) and found that plaque erosion was a predictable
clinical entity distinct from plaque rupture in STEMI patients. Indeed,
at the multivariable analysis, age <50 years, current smoking, absence
of other coronary risk factors, lack of multi-vessel disease, reduced
lesion severity, larger vessel size, and nearby bifurcation were signifi-
cantly associated with plaque erosion.20 Substantial differences be-
tween plaque erosion and plaque fissure were also found by
Sugiyama et al.21 who performed three-vessel OCT in 51 patients
with ACS and observed that compared with those with culprit plaque
rupture, patients with plaque erosion had a smaller number of non-
culprit plaques and the lower levels of panvascular instability, affirm-
ing that distinct pathophysiologic mechanisms operate in plaque
erosion and plaque rupture.
Finally, in a mechanistic study, Pedicino et al.22 evaluated the gene/
protein expression of HYAL2 (enzyme degrading hyaluronan to its
pro-inflammatory 20 kDa isoform) and of the hyaluronan-receptor
CD44 (Figure 2). Gene and protein expression of HYAL2 and
CD44v6 were higher in patients with plaque erosion when compared
with those with plaque rupture. HYAL2 might represent a potential
new biomarker in ACS. This clinical study shows that plaque erosion
is characterized by a profound alteration of hyaluronan metabolism
and that, after further validation, HYAL2 might represent a potentially
useful biomarker for the non-invasive identification of this mechanism
of coronary instability.
New insight into post-myocardial
infarction remodelling
In an elegant experimental study Reboll et al.23 identified Emc10 as a
previously unknown angiogenic growth factor that is produced by
Figure 1 Change in mortality of acute myocardial infarction over time (from Luscher and Obeid17).
Table 1 The fourth universal definition of myocardial
infarction (from Thygesen et al.3)
• Type 1 myocardial infarction: emphasis on the causal relationship
of plaque disruption with coronary atherothrombosis
• Type 2 myocardial infarction: settings with oxygen demand and
supply imbalance unrelated to acute coronary atherothrombosis
• Type 2 myocardial infarction: relevance of presence or absence
of coronary artery disease to prognosis and therapy
• Differentiation of myocardial injury from Type 2 myocardial
infarction
• Type 3 myocardial infarction: clarify why Type 3 myocardial
infarction is a useful category to differentiate from sudden cardiac
death
• Types 4–5 myocardial infarction: emphasis on distinction
between procedure-related myocardial injury and procedure-
related myocardial infarction
• Cardiac troponin: analytical issues for cardiac troponins
• Emphasis on the benefits of high-sensitivity cardiac troponin assays
• Considerations relevant to the use of rapid rule-out and rule-in
protocols for myocardial injury and myocardial infarction
• Issues related to specific diagnostic change (‘delta’) criteria for the
use of cardiac troponins to detect or exclude acute myocardial
injury
• Consideration of new non-rate-related right bundle branch block
with specific repolarization patterns
• ST-segment elevation in lead aVR with specific repolarization
patterns, as a STEMI equivalent
• ECG detection of myocardial ischaemia in patients with an
implantable cardiac defibrillator or a pacemaker
• Enhanced role of imaging including cardiac magnetic resonance
imaging for the diagnosis of myocardial infarction
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.bone marrow-derived monocytes and macrophages as part of an en-
dogenous adaptive response that can be enhanced therapeutically to
repair the heart after MI. In another study, Miyazaki et al. investigated
whether osteocrin (OSTN) potentially functioning as a natriuretic
peptide clearance receptor-blocking agent can be used as a new
therapeutic peptide for treating congestive heart failure after MI. In a
mouse model they found that infusion of OSTN24 resulted in an
increased plasma atrial natriuretic peptide and in an improvement of
congestive heart failure after MI as indicated by the reduced weight of
hearts and lungs and by the reduced fibrosis. Similar results were con-
firmed in a transgenic model overexpressing OSTN. Finally,
Frankenreiter et al. in a preclinical study found that lack of BK mito-
chondrial channels renders the heart more susceptible to ischaemia/
reperfusion injury, while BK channels seem to permit the protective
effects triggered by PDE5 inhibitors as well as by preconditioning.
Thus, this study establishes mitochondrial cardiomyocyte BK chan-
nels as a promising target for limiting acute cardiac damage as well as
adverse long-term events that occur after MI.25
Early diagnosis
Troponin
The timing of Tn assessment in suspected AMI admitted to the emer-
gency department remains controversial.26 Badertscher et al.27
compared the negative predictive value (NPV) for the presence of
AMI (equivalent of diagnostic safety), and the proportion of patients
triaged towards rule-out (equivalent of diagnostic accuracy) in a large
multicentre study enrolling patients presenting with suspected AMI
to the emergency department. Among 2547 patients eligible for ana-
lysis with hs-cTnT, AMI was the final adjudicated diagnosis in 387
patients (15%). The 0/1 h algorithm provided safety similar to that of
the 0/3 h algorithm [NPV 99.8%, 95% confidence interval (CI) 99.4–
99.9 vs. 99.7%, 95% CI 99.2–99.9; P 0.645] but allowed the rule-out
of significantly more patients compared with the 0/3 h algorithm
(60% vs. 44%; P< 0.001). Among 2197 patients eligible for analysis
with hs-cTnI, AMI was the final diagnosis in 327 patients (15%). The
0/1 h algorithm provided higher safety compared with the 0/3 h algo-
rithm (NPV 99.6%, 95% CI 99.1–99.9% vs. 97.8%, 95% CI 96.7–98.5;
P< 0.01) and allowed the rule-out of a similar portion of patients
compared with the 0/3 h algorithm (52% vs. 51%; P= 0.507). The
authors concluded in line with the ESC guidelines that the 0/1 h algo-
rithm is superior to the 0/3 h algorithm using hs-cTnT as well as hs-
cTnI because it more favourably combines safety with efficacy.
In a prospective multicentre diagnostic study enrolling 3254 unse-
lected patients presenting with suspected AMI to the emergency de-
partment, Twerenbold et al.28 assessed the diagnostic performance
of the ESC 0/1 h algorithm using hs-cTnT and hs-cTnI in patients with
renal dysfunction defined as an estimated glomerular filtration rate
below 60 mL/min/1.73 m. The prevalence of AMI was substantially
Figure 2 Model of plaque erosion. The figure summarizes the driving hypothesis that derives from both the existing experimental and post-mor-
tem studies on plaque erosion and the data emerging from this clinical study. Overexpression of hyaluronidase 2 in peripheral blood mononuclear
cells (membrane, cytoplasm, and nuclei) under conditions of increased shear stress (#1) leads to degradation of high-molecular-weight hyaluronan to
proinflammatory low-molecular-weight hyaluronan, which, in turn, promotes endothelial activation and detachment via TLR2 stimulation (#2), as
well as neutrophil recruitment (#3), the latter being amplified by overexpression of CD44, which is necessary and sufficient for adhesion of neutro-
phils to low-molecular-weight hyaluronan. Finally, low-molecular-weight hyaluronan induces increased platelet-monocyte binding, thus promoting
thrombus formation (#4). Scarcely represented inflammatory cells are found in the intima, close to the site of erosion (T-cells in green and foam
cells). EC, endothelial cell; ECM, extracellular matrix; HA, hyaluronan; HMW-HA, high-molecular-weight hyaluronan; HYAL2, hyaluronidase 2;
LMW-HA, low-molecular-weight hyaluronan; PBMC, peripheral blood mononuclear cell; PMNc, polimorphonuclear cell (from Pedicino et al.22).
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higher in patients with than in those without renal dysfunction (31%
vs. 13%, P< 0.001). Importantly, using hs-cTnT, the percentage of
patients eligible for rule-out was much lower among patients with
than among those without renal dysfunction (18% vs. 68%,
P< 0.001). Similar findings were observed with hs-cTnI. The authors
conclude that many of the challenges in patients with renal dysfunc-
tion admitted to emergency department with suspected AMI are
related to the high prevalence of commonly yet undiagnosed cardiac
comorbidities including hypertensive heart disease and diabetic car-
diomyopathy associated with chronic cardiomyocyte injury and
therefore increases in hs-cTn plasma concentrations and an increased
prevalence of ECG abnormalities. These challenges need to be
addressed in future studies.
Cardiac myosin-binding protein
In 1954, unselected patients presenting to the emergency depart-
ment with symptoms suggestive of AMI, Kaier et al. measured con-
centrations of Cardiac Myosin-Binding Protein C (cMyC) and hs-cTn
at presentation. In 17% of the patients, the final diagnosis was AMI.29
The final diagnosis of AMI was independently adjudicated using all
available clinical and biochemical information without knowledge of
cMyC. Discriminatory power for AMI, as quantified by the area under
the receiver operating characteristic curve was comparable for
cMyC, hs-cTnT (0.927) and hs-cTnI (0.922) and superior to cTnI
measured by a contemporary sensitivity assay (0.909). In early pre-
senters (chest pain <3 h), the improvement in rule-in/rule-out classifi-
cation with cMyC was larger compared with hs-cTnT and hs-cTnI
(both P< 0.001). The authors conclude that cMyC at presentation
provides discriminatory power comparable to hs-cTnT and hs-cTnI
in the diagnosis of AMI, and may perform favourably in patients pre-
senting early after symptom onset. A limitation of this study is lack of
comparison of cMyC performance vs. the 0/1 h algorithm by hs-cTn
proposed in this setting by the European Society of Cardiology.
Risk stratification
Biomarkers
Klingenberg et al. found that in coronary thrombi of ACS patients,
cysteine-rich angiogenic inducer 61 (Cyr61 or CCN1) gene tran-
scripts were highly up-regulated compared with peripheral mono-
nuclear cells. Furthermore, in a murine ischaemia–reperfusion model,
myocardial Cyr61 expression was markedly increased compared
with the controls.30 Cyr61 levels were determined in human serum
using an enzyme-linked immunosorbent assay in 2168 ACS patients
referred for coronary angiography. Cyr61 improved risk stratification
for all-cause mortality when added to the reference GRACE risk
score at 30 days (C-statistic 0.88–0.89, P= 0.001) and 1 year (C-stat-
istic 0.77–0.80, P< 0.001) and was comparable to hs-cTn (30 days:
0.88–0.89, P< 0.001; 1 year: 0.77–0.79, P< 0.001). Similar results
were obtained for the composite endpoint of all-cause mortality or
MI.
Several other biomarkers (including clot lysis time, macrophage
migration inhibitory factor, circulating progenitor cells, and interleu-
kin-8) have been found to predict cardiovascular outcome after ACS
in studies published during the last year.31–34 It remains to establish
their incremental utility in the clinical arena in addition to validated
risk predictors and which of these biomarkers might become thera-
peutic target.
Cardiac magnetic resonance
De Waha et al.35 performed a pooled analysis using individual patient
data from seven randomized primary PCI trials and 1688 patients in
which microvascular obstruction was assessed within 7 days after
reperfusion by CMR using late gadolinium enhancement imaging
(Figure 3). Microvascular obstruction was present in 960 (56.9%) of
patients, and median microvascular obstruction [percent left ven-
tricular (LV) myocardial mass] was 0.47% (IQR 0.00–2.54). A graded
response was present between the extent of MVO (per 1.0% abso-
lute increase) and subsequent mortality [Cox adjusted hazard ratio
(HR) 1.14, 95% CI 1.09–1.19; P< 0.0001] and hospitalization for HF
(Cox adjusted HR 1.08, 95% CI 1.05–1.12; P< 0.0001). Microvascular
obstruction remained significantly associated with all-cause mortality
even after further adjustment for infarct size (Cox adjusted HR 1.09,
95% CI 1.01–1.17; P= 0.03). This patient-level meta-analysis confirms
that microvascular obstruction is frequent after apparently successful
primary PCI and portends a worse outcome. Its prevention and treat-
ment remain an unmet need.
Provocative tests in myocardial infarction
with no obstructive atherosclerosis
Montone et al.36 prospectively evaluated 80 consecutive patients
with a diagnosis of MI with no obstructive coronary atherosclerosis
(MINOCA), excluding patients with aetiologies other than suspected
coronary vasomotor abnormalities and performed an invasive pro-
vocative test using acetylcholine or ergonovine immediately after
coronary angiography. Provocative test was positive in 46.2% of the
patients without any complication. Among patients with a positive
test, epicardial spasm was detected in 64.9% patients and microvascu-
lar spasm in 35.1% patients. After a median follow-up of 36 months,
patients with a positive test had a significantly higher occurrence of
death from any cause (32.4% vs. 4.7%), cardiac death (18.9% vs.
0.0%), and readmission for ACS (27.0% vs. 7.0%) as well as a worse
angina status as assessed by Seattle Angina Questionnaire (Seattle
score: 88 vs. 100) when compared with patients with a negative test
(Figure 4). The authors conclude that in patients presenting with
MINOCA and suspected coronary vasomotor abnormalities, a posi-
tive provocative test for spasm is safe and identifies a high-risk subset
of patients. These findings support the recommendation given in the
European Guidelines on STEMI,37 which recommend an accurate
diagnostic work up in patients with MINOCA in order to establish its
cause and an appropriate aetiological treatment.
Acute coronary syndromes in
women
Radial vs. femoral access
Gargiulo et al sought to investigate the comparative efficacy and
safety outcomes across sex of radial vs. femoral access in ACS
patients participating in the MATRIXA-Access (Minimizing Adverse
Haemorrhagic Events by TRansradial Access Site and Systemic
Implementation of angioX) trial. Among 8404 patients, 26.6% were
274 P. Widimsky et al.
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women and 73.4% were men.38 Men had a lower risk of access site
bleeding [male vs. female rate ratio (RR) 0.64; P= 0.0016], severe
bleeding (RR 0.17; P= 0.0012), and transfusion (RR 0.56; P= 0.0089).
When comparing radial vs. femoral, there was no significant inter-
action for MACCE and NACE stratified by sex (Pint = 0.15 and 0.18,
respectively), although for both coprimary endpoints the benefit with
transradial access was relatively greater in women (RR 0.73;
P= 0.019; and RR 0.73; P= 0.012, respectively). Similarly, there was
no significant interaction between male and female patients for the in-
dividual endpoints of all-cause death (Pint = 0.79), MI (Pint = 0.25),
stroke (Pint = 0.18), and Bleeding Academic Research Consortium
Type 3 or 5 (Pint = 0.45).
Sex differences in high-intensity statin
use
Peters et al. studied 16 898 U.S. adults <65 years of age with commer-
cial health insurance of which 26% were women and 71 358 U.S.
adults >66 years of age with government health insurance of which
49% were women. They had filled statin prescriptions within 30 days
after hospital discharge for MI.39 The adjusted risk ratio for filling a
high-intensity statin comparing women with men was 0.91 (95% CI
0.90–0.92). Women were less likely than men to fill high-intensity sta-
tins within all subgroups analysed, and the disparity was largest in the
youngest and oldest adults and for those without prevalent comorbid
conditions. Thus, despite recent efforts to reduce gender differences
in guideline-recommended therapy, women continue to be less likely
than men to fill a prescription for high-intensity statins following hos-
pitalization for MI. The underlying reasons for this disparity require
further study.
Long term-outcome
Takotsubo syndrome
Ghadri et al. compared long-term mortality of patients with
Takotsubo syndrome (TTS) from the International Takotsubo
Registry to an age- and sex-matched cohort of patients with ACS. In
addition, short- and long-term outcomes were compared between
different groups according to triggering conditions.40 Overall, 1613
TTS patients had a comparable long-term mortality risk with ACS
patients. TTS patients triggered by physical stress showed higher
mortality rates than ACS patients during long-term follow-up, where-
as TTS triggered by emotional stress had better outcomes their ACS
Figure 3 Time-to-first event analysis (from time of study entry) according to a four-level categorical variable including (i) microvascular obstruc-
tion <_ median and infarct size <_ median, (ii) microvascular obstruction > median and infarct size <_ median, (iii) microvascular obstruction <_ median
and infarct size > median, and (iv) microvascular obstruction > median and infarct size > median. MVO, microvascular obstruction in patients admit-
ted with ST segment elevation myocardial infarction and submitted to primary percutaneous intervention. Infarct size and microvascular obstruction
were assessed by cardiac magnetic resonance (from de Waha et al.35).
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Figure 4 Survival Kaplan–Meier curves according to provocative test response (from Montone et al.36). Patients with a positive test had a signifi-
cantly higher occurrence of both death from any causes [12 (32.4%) vs. 2 (4.7%); P= 0.002] and cardiac death [7 (18.9%) vs. 0 (0.0%); P= 0.005] and
had a higher rate of readmission for acute coronary syndromes [10 (27.0%) vs. 3 (7.0%); P= 0.015] compared with patients with a negative test.
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comparators. As a consequence, the authors propose a new classifi-
cation based on triggers, which can serve as a clinical tool to predict
short- and long-term outcomes of TTS (Table 2).
Medical treatment
Antithrombotic therapy
Anti-platelet drugs
After an ACS dual anti-platelet therapy for 12 months is the default
anti-thrombotic regimen irrespective of treatment modality.
Whether a shorted period of 6 months dual antiplatelet therapy
(DAPT) may be non-inferior to 12 or more months was investigated
in the SMART-DATE trial.41 A total of 2712 ACS patients undergoing
PCI were randomly assigned to 6 months DAPT or 12 months (or
longer). The primary endpoint was a composite of all-cause death,
MI, or stroke at 18 months. While the non-inferiority margin was met
(cumulative event rate 4.7% vs. 4.2%; absolute risk difference 05%;
upper limit of one-sided 95% CI 1.8%; P non-inferiority = 0.03 with a
predefined non-inferiority margin of 2.0%), MI occurred more fre-
quently in the 6-month DAPT group (24 [1.8%] patients vs. 10
[0.8%]; 2.41 [1.15–5.05]; P= 0.02). Furthermore, there were numer-
ically more stent thrombosis in the 6-month DAPT group [15 (1.1%)
patients in the 6-months DAPT group vs. 10 (0.7%) patients in the
12-month or longer DAPT group; P= 0.32]. Therefore, the safety of
a shortened DAPT duration after ACS cannot be proclaimed.
The two potent P2Y12 inhibitors ticagrelor and prasugrel were
compared in ACS patients in the PRAGUE-18 trial.42 A total of 1230
ACS patients were randomized to either treatment option on the
background of continued ASA use. The combined endpoint was car-
diovascular death, MI, or stroke at 1 year. No significant differences
were observed for the primary endpoint (6.6% of prasugrel patients
vs. 5.7% of ticagrelor patients; HR 1.167, 95% CI 0.742–1.835;
P= 0.503), cardiovascular death (3.3% vs. 3.0%; P= 0.769), MI (3.0%
vs. 2.5%; P= 0.611), stroke (1.1% vs. 0.7%; P= 0.423), all-cause death
(4.7% vs. 4.2%; P= 0.654), definite stent thrombosis (1.1% vs. 1.5%;
P= 0.535), and all bleeding (10.9% vs. 11.1%; P= 0.999). Thus, it
appears that both potent P2Y12 inhibitors are similar in their
effectivity.
De-escalation from a potent of P2Y12 inhibitor to clopidogrel is an
alternative treatment strategy in ACS patients especially in cost sensi-
tive environments. In the TROPICAL ACS trial43 patients were ran-
domly assigned to either standard treatment with prasugrel for
12 months (control group) or to a guided de-escalation regimen
(1 week prasugrel followed by 1 week clopidogrel and platelet func-
tion testing guided maintenance therapy with clopidogrel or prasu-
grel from day 14 after hospital discharge; guided de-escalation
group). When the impact of age, as a continuous variable, was ana-
lysed on the primary endpoint (cardiovascular death, MI, stroke, or
bleeding >_ Grade 2 according to Bleeding Academic Research
Consortium criteria) after guided de-escalation vs. control treatment,
an increasing relative risk reduction was observed by decreasing age
(P= 0.02), due to significant reductions in bleeding. In elderly patients
(age >70, n= 370), the absolute risk of events was higher without sig-
nificant differences between guided de-escalation vs. control group
(15.5% vs. 13.6%; HR 1.17, 95% CI 0.69–2.01; P= 0.56). Guided de-
escalation for P2Y12 inhibitors depend on patient’s age with younger
patients deriving a significant net clinical benefit.
The GLOBAL LEADERS trial44 included 15991 all-comer PCI
patients [ACS including STEMI or stable coronary artery disease
(CAD)] and compared short dual antiplatelet regimen (DAPT) with
ASA plus ticagrelor given only during the first month and followed by
ticagrelor 90 mg bid monotherapy vs. guideline-recommended ther-
apy (1-year DAPT, followed by ASA monotherapy). The primary
endpoint of all-cause mortality or new Q-wave MI at 2 years dis-
played a statistical trend: 3.8% ticagrelor monotherapy vs. 4.4% 1
year DAPT (RR 0.87, 95% CI 0.75–1.01; P= 0.073). All-cause mortal-
ity at 2 years was not different: 2.81% ticagrelor monotherapy vs.
3.17% one year DAPT (P= 0.182). Interestingly, the results were al-
most exactly the same among ACS and among stable CAD patients.
Oral anticoagulants
Oral anticoagulation (OAC) is indicated in patients with atrial fibrilla-
tion (AF) at increased risk for stroke. After an ACS a combination of
OAC with antiplatelet therapy is warranted in AF patients. Four
randomized trials have compared anti-thrombotic regimens including
the combination of DAPT with OAC or a single antiplatelet with
OAC in this scenario. In a meta-analysis,45 the safety and efficacy of
dual vs. triple antithrombotic therapy was studied (Figure 5).
Compared with the triple therapy arm, thrombolysis in myocardial
infarction (TIMI) major or minor bleeding showed a reduction by
47% in the dual therapy arm [4.3% vs. 9.0%; HR 0.53, 95% credible
interval (CrI) 0.36–0.85, I2 = 42.9%]. There was no difference in the
trial-defined major adverse cardiac events (MACE) (10.4% vs. 10.0%,
HR 0.85, 95% CrI 0.48–1.29, I2 = 58.4%), or in individual outcomes of
all-cause mortality, cardiac death, MI, stent thrombosis, or stroke be-
tween the two arms. These findings support the concept that dual
therapy (one anticoagulant þ one antiplatelet drug) may be a better
option than triple therapy (one anticoagulant þ two antiplatelet
drugs) in many patients with AF following PCI.
The important yet not definitely resolved question whether triple
or dual antithrombotic therapy after MI should be used in patients
with AF undergoing PCI was further investigated in a study based on
the Swedish registries.46 The study included n= 7116 patients with
AF undergoing PCI during AMI. Landmark analysis was done for the
first 3 months (0–90 days) and for 91–365 days. At discharge, 16.2%
received triple therapy (ASA, clopidogrel, and warfarin), 1.9% ASA
plus warfarin, 7.3% clopidogrel plus warfarin, and 60.8% dual antipla-
telets (Table 3).
.................................................................................................
Table 2 Proposal for a new classification of Tako-
Tsubo syndrome based on triggers (based on Ghadri
et al.40)
Class I TTS related to emotional stress
Class II TTS related to physical stress including diseases
Class IIa TTS secondary to physical activities, medical conditions, or
procedures
Class IIb TTS secondary to neurologic disorders
Class III TTS without an identifiable triggering factor
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..Besides AF, the detection of a LV thrombus warrants initiation of
OAC in ACS patients because of an increased risk of systemic embol-
ism (SE). Such an event occurred in 16.3% of patients with LV thrfom-
bus and 2.9% of patients without LV thrombus in a study by
Maniwa.47 A multivariate analysis showed that LV thrombus was an
independent predictor for SE in ACS patients. Among 84 patients
treated with vitamin K antagonists, 34 patients within the therapeutic
range >_50% of time were compared with 50 within TTR <50% of
time. Only one embolic event (2.9%) developed in those within the
therapeutic range >_50% of time, while nine embolic events (19%)
developed in the <50% group (P= 0.036). While patients with LV
thrombus seem to benefit from OAC, the optimal duration of OAC
Figure 5 Summary of bleeding risks and ischaemic risks with dual vs. triple antithrombotic therapy (from Golwala et al.45). All the four trials have
demonstrated a reduction in bleeding with dual therapy compared with triple therapy, but dual therapy may not only reduce bleeding events but is
comparable to triple antithrombotic therapy for the reduction of major adverse cardiovascular events.
....................................................................................................................................................................................................................
Table 3 Triple vs. dual antithrombotic therapy after myocardial infarction in patients with atrial fibrillation under-
going PCI (data from Batra et al.,46 DAPTwas used as reference treatment)
Triple therapy ASA1warfarin Clopidogrel 1 warfarin
Cardiovascular outcome adjusted HR
0–90 days 0.86 (0.70–1.07) 0.82 (0.54–1.26) 0.90 (0.68–1.19)
91–365 days 0.78 (0.58–1.05) 0.62 (0.48–0.79) 0.68 (0.49–0.95)
Major bleeds adjust. HR
0–90 days 2.16 (1.48–3.13) 1.30 (0.60–2.85) 1.28 (0.71–2.32)
91–365 days 1.61 (0.98–2.66) 1.01 (0.63–1.62) 1.08 (0.57–2.04)
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for this indication is still uncertain and would need interpretation in
the context of the neutral COMMANDER trial (with rivaroxaban48)
and possibly further trials.
The addition of OAC with rivaroxaban 2.5 mg orally twice daily to
DAPT with ASA and clopidogrel was investigated in the ATLAS
ACS-2 TIMI 51 trial. In a post hoc analysis49 fatal and irreversible effi-
cacy events including non-bleeding cardiovascular death, MI, and is-
chaemic stroke were compared with fatal or irreversible safety
events, including fatal and intracranial bleeding. The addition of low
dose rivaroxaban to DAPT was associated with 115 (95% CI 18–
212) fewer fatal or irreversible ischaemic events (663 for placebo vs.
548 for therapy) and 10 (95% CI -11 to 32) additional fatal or irre-
versible seriously harmful events (33 vs. 23 for placebo) per 10 000
patient-years of exposure. The authors conclude that there was a net
reduction in fatal or irreversible events for ACS patients when low
dose rivaroxaban is added to DAPT.
Periprocedural anticoagulation
The latest ESC guidelines on revascularization50 have downgraded
the recommendation for bivalirudin as anticoagulant during primary
PCI. In the VALIDATE-SWEDEHEART trial51 with 6006 ACS
patients [3005 with STEMI and 3001 with ST-segment elevation myo-
cardial infarction (NSTEMI)] randomized to bivalirudin or heparin
during primary PCI at 180 days, a primary Endpoint event occurred in
12.3% of the patients (369 of 3004) in the bivalirudin group and in
12.8% (383 of 3002) in the heparin group (HR 0.96, 95% CI 0.83–
1.10; P= 0.54). Definite stent thrombosis was observed in 0.4%
patients with bivalirudin and 0.7% patients with heparin, (HR 0.54,
95% CI 0.27–1.10; P= 0.09).
In the MATRIX trial,52 7213 patients were randomly assigned to
receive either bivalirudin or heparin with or without GPIs at discre-
tion of the operator. Thus also here the rates of MACE (a composite
of death, MI, or stroke) were not significantly lower in ACS patients
receiving bivalirudin than in those receiving heparin, irrespective of
GPI use.
Lipid lowering agents
ODYSSEY OUTCOMES trial enrolled 18 924 patients after an ACS
with low-density lipoprotein cholesterol level of at least 1.8 mmol
per liter in spite of statins at the maximal tolerated dose. Patients
were randomized to alirocumab or placebo. The median duration of
follow-up was 2.8 years. A primary endpoint event occurred in 903
(9.5%) patients in the alirocumab group and in 1052 (11.1%) patients
in the placebo group (HR 0.85, 95% CI 0.78–0.93; P< 0.001).
Mortality was lower after alirocumab [3.5% (334 patients) vs. 4.1%
(392 patients), HR 0.85; 95% CI 0.73–0.98]. There was no difference
in safety measures.53
The US authors reviewed the new data for the 2018 guidelines on
the management of blood cholesterol.54 The use of ezetimibe/sim-
vastatin vs. simvastatin in IMPROVE-IT trial reduced the primary out-
come by 1.8% over 7 years (HR 0.90; 95% CI 0.84–0.96, 7-year
number needed to treat: 56). The PSCK9 inhibitor evolocumab in
the FOURIER study decreased the primary outcome by 1.5% over
2.2 years (HR 0.80; 95% CI 0.73–0.88; 2.2 = year number needed to
treat: 67). The ODYSSEY OUTCOMES trial is described above. For
ezetimibe and the PSCK9 inhibitors, rates of musculoskeletal,
neurocognitive, gastrointestinal, or other adverse event risks did not
differ between the treatment and control groups.
Oxygen therapy
Whether supplemental oxygen in patients with STEMI impacts on
procedure-related and clinical outcomes was studied in a pre-
specified Subgroup analysis of the DETO2X-AMI trial.55 A total of
1361 STEMI patients were assigned to receive oxygen, and 1446
assigned to ambient air. The pre-specified primary composite end-
point of all-cause death, rehospitalization with MI, cardiogenic shock,
or stent thrombosis at 1 year occurred in 6.3% (86 of 1361) of
patients allocated to oxygen compared with 7.5% (108 of 1446) allo-
cated to ambient air (HR 0.85, 95% CI 0.64–1.13; P= 0.27). In accord-
ance with current guidelines the routine use of supplemental oxygen
in normoxemic patients with STEMI undergoing primary PCI was not
beneficial (Figure 6).
Interventional therapy
During the last year, a lot of very interesting new data on PCI in ACS
were published. Below are selected studies about peri-/post-proced-
ural medication, about revascularization strategy in STEMI and
NSTEMI, bioresorbable scaffolds (BRS), thrombus aspiration, frac-
tional flow reserve, and spontaneous coronary dissection.
Peri-procedural pharmacological
treatment
The SECURE PCI study56 investigated atorvastatin pre-treatment be-
fore PCI for ACS. Periprocedural loading dose of atorvastatin did not
decrease 30-day MACE in patients with ACS and planned invasive
management in the SECURE PCI trial. This trial was conducted at 53
sites in Brazil among 4191 patients with ACS and planned PCI.
Patients were randomized to receive two loading doses of 80 mg of
atorvastatin (n= 2087) or matching placebo (n= 2104) before and
24 h after a planned PCI. All patients received 40 mg of atorvastatin
for 30 days starting 24 h after the second dose of study medication.
Only 64.7% patients underwent PCI, 8% underwent coronary artery
bypass graft surgery, and 27.3% had medical management alone. At
30 days, 6.2% patients in the atorvastatin group and 7.1% in the pla-
cebo group had a MACE (absolute difference 0.85%, 95% CI -0.70%
to 2.41%; HR 0.88, 95% CI 0.69–1.11; P = 0.27). These findings do not
support the routine use of loading doses of atorvastatin among unse-
lected patients with ACS and intended invasive management.
Multivessel percutaneous coronary
intervention in haemodynamically stable
ST-segment elevation myocardial
infarction
A meta-analysis of 11 randomized trials comparing complete revascu-
larization with culprit-only revascularization in patients with STEMI
without cardiogenic shock included 3561 patients.57 Compared with
a culprit-only strategy, complete revascularization significantly
reduced risk for death or MI [relative risk (RR) 0.76, 95% CI 0.58–
0.99; P= 0.04]. Meta-regression showed that performing complete
revascularization at the time of primary PCI was associated with
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.better outcomes (P= 0.016). The six trials performing complete
revascularization during primary PCI (immediate revascularization)
were associated with a significant reduction in risk for both total mor-
tality (RR 0.62, 95% CI 0.39–0.97; P= 0.03) and MI (RR 0.40, 95% CI
0.25–0.66; P< 0.001), whereas the five trials performing only staged
revascularization did not show any significant benefit in either total
mortality (RR 1.02, 95% CI 0.65–1.62; P= 0.87) or MI (RR 1.04, 95%
CI 0.48–1.68; P= 0.86). The limitation however was, that some of
these trials allowed staged revascularization to be performed with a
delay, during second hospital stay. Thus, data are still inconclusive
whether complete revascularization in haemodynamically stable
STEMI should be performed as a single procedure (i.e. during primary
angioplasty) or as two procedures during the single (initial) hospital
stay.
Chronic total occlusion (CTO) in a noninfarct-related artery (non-
IRA) in patients with STEMI is linked to increased mortality. It remains
unclear whether staged revascularization of a non-IRA CTO in
patients with STEMI translates to improved outcomes. This meta-
analysis (6 studies, 1253 patients) compared outcomes between
patients presenting with STEMI with concurrent CTO who under-
went PCI of noninfarct-related artery CTO vs. those who did not.58
There was a significant difference in major adverse cardiovascular
events [odds ratio (OR) 0.54; 95% CI 0.32–0.91], cardiovascular
mortality (OR 0.43; 95% CI 0.20–0.95), and heart failure readmissions
(OR 0.57; 95% CI 0.36–0.89), favouring patients in the CTO PCI
group. No significant differences were observed between the two
groups for all-cause mortality (OR 0.47; 95% CI 0.22–1.00), MI (OR
0.78; 95% CI 0.41–1.46), repeat revascularization (OR 1.13; 95% CI
0.56–2.27), and stroke (OR 0.51; 95% CI 0.20–1.33).
Multivessel percutaneous coronary
intervention in ST-segment elevation
myocardial infarction with cardiogenic
shock
The CULPRIT-SHOCK trial compared culprit PCI vs. multivessel PCI
in patients with AMI and cardiogenic shock. This trial randomized
706 patients to culprit lesion only PCI (with possible staged revascu-
larization) vs. immediate multivessel PCI performed during the acute
index procedure. The outcomes at 30 days (presented in 2017) dem-
onstrated lower all-cause mortality of 43.3% after culprit-only PCI
compared with 51.5% after acute multivessel PCI (P= 0.03). One-
year all-cause mortality was also lower after culprit only PCI but the
P-value failed to reach significance (50% vs. 57%, P= 0.07). Landmark
analysis confirmed, which the mortality benefit from culprit-only PCI
is confined to the initial 30 days.59
Figure 6 The Kaplan–Meier curves for the composite of all-cause death, rehospitalization with myocardial infarction, cardiogenic shock, or stent
thrombosis major adverse cardiac event up to 365 days. Enrolled ST-elevation myocardial infarction patients were randomized to either oxygen ther-
apy at a moderate flowrate of 6 L/min for a median of 10.36 h or ambient air (from Hofmann et al.55).
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The analysis of 659 STEMI patients with multivessel CAD present-
ing with cardiogenic shock and undergoing primary PCI in Korea (the
KAMIR-NIH registry60) retrospectively compared 260 patients with
multivessel PCI and 399 with IRA-only PCI. The risk of all-cause death
was significantly lower in the multivessel PCI group than in the IRA-
only PCI group (21.3% vs. 31.7%; HR 0.59, 95% CI 0.43–0.82;
P= 0.001). Multivessel PCI was independently associated with
reduced risk of 1-year all-cause death and patient-oriented compos-
ite outcome. The authors conclude, that multivessel PCI for com-
plete revascularization may be a reasonable strategy to improve
outcomes in patients with STEMI and cardiogenic shock. However,
these are just registry result and contrast the higher level of evidence
from the randomized CULPRIT-SHOCK trial discussed above.
Thus, currently, there is sufficient evidence to recommend the
best possible strategy for STEMI with multivessel disease: (i) only the
culprit artery (IRA) should be treated in the acute phase during the
index procedure—unless a critical, flow limiting lesion is present in
another artery and (ii) patient should be discharged home with com-
plete revascularization whenever possible (i.e. pre-discharge staged
PCI is recommended). Unfortunately, health care reimbursement
systems in many countries stimulate a less optimal strategy—staged
PCI during second hospital stay usually offers better reimbursement.
Stents and percutaneous coronary
intervention techniques
The European Absorb Consortium61 presented outcomes of 10.312
patients treated with everolimus-eluting BRS during routine clinical
practice. Overall 12 months mortality was 1.2%, cardiac death 0.6%,
any MI 2.7% and definite or probable scaffold thrombosis 1.6% (34
cases acute—63 subacute—60 late). Landmark analysis with a pre-
specified landmark set at 30 days showed a scaffold thrombosis rate
at 30 days of 0.94% which decreased between 1 month and
12 months to 0.58%. No predilatation, bifurcation lesion and DAPT
interruption carried the highest risk for scaffold thrombosis. The
study demonstrated favourable clinical outcome data for BVS, with
target lesion failure comparable to data of second-generation DES.
Clinical outcome after treatment with everolimus-eluting BRS might
be improved by specific implantation protocols.
One single-centre descriptive registry62 of 657 patients, who
received 925 coronary BRS, described different mechanisms underly-
ing early and late BRS thrombosis (ScTs). Twenty-eight ScTs were
recorded: 14 early (2.2%), 5 late (0.9%), and 9 very late (1.7%).
Incomplete BRS deployment was a predictor of the early scaffold
thrombosis, while late thrombosis was associated with large vessel
size and BRS undersizing.
Routine thrombus aspiration is now Class III indication during PCI
in STEMI. This is largely based on the TOTAL (and TASTE63) trials. In
a follow-up paper,64 the authors demonstrated the risks of overinter-
preting the interim data and prematurely stopping a trial. Should such
approach be used in the TOTAL trial, the key finding of increased
stroke risk related to thrombus aspiration during primary PCI would
never have been detected.
The FUTURE trial65 analysed, whether in multivessel disease
patients FFR helps to guide decision making for PCI or coronary artery
bypass graft (CABG) or medical treatment only and thereby improves
clinical prognosis compared with traditional management. All-comer
patients with stable or stabilized angina and multivessel disease includ-
ing LAD were randomized at the time of angiography to either FFR-
guided or angio-guided decision making. Recruitment was stopped at
938 patients after DSMB recommendation due to an increased all-
cause mortality in the FRR-guided arm (3.7% vs. 1.5%, HR 2.39, 95% CI
1.05–5.43; P= 0.038). Medical treatment alone was recommended for
17% patients in the FFR-guided arm vs. 9% in the angio-guided arm.
There was no difference in the primary Endpoint (all-cause mortality þ
myocardial Infarctionþ repeat revascularizationþ stroke) at 1 year.
Some authors have questioned whether primary PCI performed
during the off-hours can achieve the same results as that performed
during the working hours. Reinstadler et al.66 found no significant dif-
ferences in myocardial damage following primary PCI whether under-
taken during or after routine working hours. These data suggest
efficacy and safety for primary PCI in STEMI patients independent of
the time of revascularization in contemporary health care systems.
Invasive strategy in non-ST-segment
elevation myocardial infarction
A randomized, investigator-initiated, parallel-group trial67 evaluated
the long-term effects of immediate invasive intervention in 323
patients with NSTEMI assigned to either immediate (median time to
intervention 1.4 h) or delayed (61.0 h) invasive strategy. After 3 years
follow-up, immediate invasive intervention was associated with a
lower rate of death or new MI, compared with a delayed invasive
strategy [12.3% (20/162 patients) vs. 22.5% (36/161 patients), HR
0.50, 95% CI 0.29–0.87; P= 0.014]. The observed benefit of immedi-
ate intervention was mainly driven by an increased early reinfarction
risk in delayed strategy. Three-year mortality was 9.3% in the immedi-
ate invasive strategy, and 10.0% in the delayed strategy (P= 0.83).
The VERDICT trial68 displayed only a non-significant trend to-
wards better clinical outcomes with very early (median 4.7 h) coron-
ary angiography compared with angiography performed after a
median time of 61.6 h from randomization. However, this trend be-
came significant in a subgroup of patients with GRACE risk score
>140.
Left main percutaneous coronary
intervention
The DELTA-2 registry69 enrolled 3986 consecutive patients with un-
protected left main coronary artery stenosis treated by PCI with
second-generation drug-eluting stents. The results were compared
with those from the historical DELTA 1 CABG cohort using propen-
sity score stratification. At a median of 501 days of follow-up, the oc-
currence of the primary endpoint of death, MI, or stroke was lower
in the PCI DELTA 2 group compared with the historical DELTA 1
CABG cohort (10.3% vs. 11.6%; adjusted HR 0.73, 95% CI 0.55–0.98;
P L’ 0.03). Of note, an advantage of PCI was observed with respect to
stroke (0.8% vs. 2.0%; adjusted HR 0.37, 95% CI 0.16–0.86; P L’ 0.02),
while an advantage of CABG was observed with respect to target
vessel revascularization (14.2% vs. 2.9%; adjusted HR 3.32, 95% CI
2.12–5.18; P< 0.0001).
Spontaneous coronary dissection
The multicentre Canadian Spontaneous Coronary Artery Dissection
(SCAD) Cohort Study70 included 750 patients presenting with non-
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..atherosclerotic ACS and documented SCAD on coronary angiog-
raphy confirmed by core laboratory analysis. The most typical patient
was a young (or middle aged) woman. Stress (emotional or physical)
was the most frequent precipitating factor, while fibromuscular dys-
plasia was the most frequent predisposing condition. TIMI flow 3 was
preserved in 64% patients on the initial angiogram. Thus, 86% of the
patients were treated conservatively and only one patient (0.1%)
died.
What’s next
What is the next frontier? The biggest unmet need is effective man-
agement of patients presenting with cardiogenic shock or after being
resuscitated because of sudden cardiac death. Indeed, mortality had
not changed over the last decade and is still in the range of 40–60% at
1 year,71 while those presenting in stable conditions enjoy a survival
rate of up to 98% in-hospital and 90% at 1 year (Figure 1). What
should be done to reduce mortality in this patient population? The
first minutes after cardiac arrest are the most crucial ones. Everybody
should master cardiopulmonary resuscitation in order to prevent ir-
reversible neurological damage—and here we have to fill an educa-
tional gap within the population at large. Then, the door-to-balloon-
time should be shortened further by fast tracks in the hospitals.
Third, percutaneous pumps and assist devices are novel tools to
overcome the acute haemodynamic problems, unload the left ven-
tricle, avoid multiorgan damage, and potentially allow for recovery of
pump function. However, the intra-aortic balloon pump proved inef-
fective and the Impella and extracorporeal membrane oxygenation
remains to be tested properly. Forth, novel anti-inflammatory strat-
egies,72 as recently documented in the CANTOS Trial73 might help
to reduce infarct size and facilitate haemodynamic recovery. And fi-
nally, there is still hope that stem cell therapies might assist in regen-
erating the heart muscle after an infarction in the future, once we will
find the right way to reactivate regenerative pathways as is possible in
fish and amphibia.74–77
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